C1P Stock Overview
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Consun Pharmaceutical Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.54 |
| 52 Week High | HK$0.76 |
| 52 Week Low | HK$0.50 |
| Beta | 0.62 |
| 1 Month Change | -18.94% |
| 3 Month Change | -5.31% |
| 1 Year Change | -0.93% |
| 3 Year Change | 23.84% |
| 5 Year Change | -11.13% |
| Change since IPO | 24.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| C1P | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -23.0% | 2.5% | 1.8% |
| 1Y | -0.9% | -27.7% | 2.2% |
Return vs Industry: C1P exceeded the German Pharmaceuticals industry which returned -31.9% over the past year.
Return vs Market: C1P matched the German Market which returned -0.3% over the past year.
Price Volatility
| C1P volatility | |
|---|---|
| C1P Average Weekly Movement | 16.4% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C1P's share price has been volatile over the past 3 months.
Volatility Over Time: C1P's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,127 | Meng An | www.chinaconsun.com |
Consun Pharmaceutical Group Limited, an investment holding company, researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. The company operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. It offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles to treat proteinuria; Gadopentetate Dimeglumine injections for magnetic resonance image diagnostics of nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; and Iopamidol injections used for neuroradiology, angiography, and urography.
Consun Pharmaceutical Group Limited Fundamentals Summary
| C1P fundamental statistics | |
|---|---|
| Market cap | €529.76m |
| Earnings (TTM) | €101.16m |
| Revenue (TTM) | €333.97m |
5.2x
P/E Ratio1.6x
P/S RatioIs C1P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C1P income statement (TTM) | |
|---|---|
| Revenue | CN¥2.59b |
| Cost of Revenue | CN¥668.44m |
| Gross Profit | CN¥1.92b |
| Other Expenses | CN¥1.14b |
| Earnings | CN¥784.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.99 |
| Gross Margin | 74.19% |
| Net Profit Margin | 30.29% |
| Debt/Equity Ratio | 12.8% |
How did C1P perform over the long term?
See historical performance and comparisonDividends
10.7%
Current Dividend Yield41%
Payout RatioDoes C1P pay a reliable dividends?
See C1P dividend history and benchmarks| Consun Pharmaceutical Group dividend dates | |
|---|---|
| Ex Dividend Date | Jun 11 2024 |
| Dividend Pay Date | Jun 21 2024 |
| Days until Ex dividend | 48 days |
| Days until Dividend pay date | 58 days |
Does C1P pay a reliable dividends?
See C1P dividend history and benchmarks